Barbara R.
- Country
- Poland
- Department
- Klinika Onkologii z Odcinkiem Dziennym
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 566 of 946 partner sites.
Specializations
Breast Cancer Research
Specializes in treating various subtypes of breast cancer, with particular emphasis on HER2-positive and hormone receptor-positive disease states.
- Early-stage breast cancer interventions
- Metastatic breast cancer treatments
- Triple-negative breast cancer therapies
Explores novel therapeutic combinations including targeted therapies, immunotherapies, and hormone-based treatments.
Colorectal Cancer Studies
Focuses on treating metastatic colorectal cancer with specific attention to molecular subtypes including KRAS/NRAS and BRAF wild-type variants.
- Advanced colorectal cancer treatments
- Targeted therapy approaches
- Combination therapy strategies
Investigates innovative treatment combinations for both first-line and recurrent disease settings.
Prostate Cancer Expertise
Specializes in treating metastatic castration-resistant prostate cancer with novel therapeutic approaches and combinations.
- Advanced prostate cancer management
- Hormone therapy resistance
- Novel therapeutic combinations
Evaluates emerging treatments for patients with progressive disease following standard therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.